IGF1R and breast cancer: Based on the preclinical and clinical correlative data presented in this paper, there is rationale for conducting trials that combine IGF-IR inhibitors with trastuzumab in the context of HER2-over-expressing breast cancer that has progressed on prior trastuzumab-containing regimens.